Product Description
Mercaptopurine is a medication used in the management and treatment of acute lymphoblastic leukemia. It is in the class of medications known as purine antagonists. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557620/)
Mechanisms of Action: Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia | Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia
Known Adverse Events: Anemia | Thrombocytopenia | Neutropenia | Anorexia | Diarrhea | Leukopenia | Macrophage Activation Syndrome | Lymphoma | T-Cell Lymphoma | Contraception
Company: G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, United States
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Colitis, Ulcerative|Histiocytosis|Leukemia|Lymphoid Leukemia|Lymphoma|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TINI 2 | P2 |
Recruiting |
Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2028-12-01 |
|
| AIEOP-BFM ALL 2017 | P3 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2028-07-14 |
|
| AIEOP-BFM ALL 2017 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia |
2028-06-07 |
|
| SJALL23H | P2 |
Not yet recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2028-05-01 |